General Information of Drug Transporter (DT)
DT ID DTD0002 Transporter Info
Gene Name ABCC2
Transporter Name Multidrug resistance-associated protein 2
Gene ID
1244
UniProt ID
Q92887
Exogenous Factors (drugs, dietary constituents, etc.) Modulating DT Activity (EFMDA)
Exogenous Factor Cyclosporine Approved Drug
DT Modulation Cyclosporine inhibits the transportation of Calcein AM by ABCC2 (IC50 = 10 microM) [1]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
DT Modulation Cyclosporine inhibits the transportation of Leukotriene C4 by ABCC2 (Ki = 4.7 microM) [2]
Affected Drug/Substrate Leukotriene C4 Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MRP2
DT Modulation Cyclosporine inhibits the transportation of Monoglucuronosyl bilirubin by ABCC2 (Ki = 21 microM) [3]
Affected Drug/Substrate Monoglucuronosyl bilirubin Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MRP2
DT Modulation Cyclosporine inhibits the transportation of Vinblastine by ABCC2 (Ki = 8.11 microM) [4]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
DT Modulation Cyclosporine inhibits the transportation of Calcein AM by ABCC2 [5]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
DT Modulation Cyclosporine inhibits the activity of ABCC2 [6], [7]
Exogenous Factor MK-571 Discontinued Drug
DT Modulation MK-571 inhibits the transportation of Ethacrynic acid glutathione by ABCC2 (IC50 = 4 microM) [8]
Affected Drug/Substrate Ethacrynic acid glutathione Modulation Type Inhibition
Cell System Spodoptera frugiperda (Sf9) cells-MRP2
DT Modulation MK-571 inhibits the transportation of Irinotecan by ABCC2 (IC50 = 50 microM) [9]
Affected Drug/Substrate Irinotecan Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MRP2
DT Modulation MK-571 inhibits the transportation of Leukotriene C4 by ABCC2 (Ki = 13.1 microM) [2]
Affected Drug/Substrate Leukotriene C4 Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MRP2
DT Modulation MK-571 inhibits the transportation of Vinblastine by ABCC2 (Ki = 26.4 microM) [4]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
DT Modulation MK-571 inhibits the transportation of Estradiol 17b-D-glucuronide by ABCC2 [10]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
Exogenous Factor Curcumin Drug in Phase 3 Trial
DT Modulation Curcumin inhibits the transportation of Ethacrynic acid glutathione by ABCC2 (IC50 = 5 microM) [1]
Affected Drug/Substrate Ethacrynic acid glutathione Modulation Type Inhibition
Cell System Spodoptera frugiperda (Sf9) cells-MRP2
DT Modulation Curcumin inhibits the activity of ABCC2 (IC50 = 5 microM) [1]
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
DT Modulation Curcumin inhibits the transportation of Resveratrol-3-O-glucuronide by ABCC2 [11]
Affected Drug/Substrate Resveratrol-3-O-glucuronide Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
DT Modulation Curcumin inhibits the activity of ABCC2 [1]
Cell System Spodoptera frugiperda (Sf9) cells-MRP2
Exogenous Factor Vinblastine Approved Drug
DT Modulation Vinblastine inhibits the transportation of Calcein AM by ABCC2 (IC50 = 21 microM) [12]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin-Darby Canine Kidney (MDCK) cells-MRP2
DT Modulation Vinblastine inhibits the activity of ABCC2 [16], [17]
Exogenous Factor Indomethacin Approved Drug
DT Modulation Indomethacin inhibits the transportation of Methotrexate by ABCC2 (IC50 = 0.06 microM) [13]
Affected Drug/Substrate Methotrexate Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MRP2
DT Modulation Indomethacin inhibits the activity of ABCC2 [14], [15]
Exogenous Factor Valspodar Discontinued Drug
DT Modulation Valspodar inhibits the transportation of Leukotriene C4 by ABCC2 (Ki = 28.9 microM) [2]
Affected Drug/Substrate Leukotriene C4 Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MRP2
DT Modulation Valspodar inhibits the transportation of Vincristine by ABCC2 [2]
Affected Drug/Substrate Vincristine Modulation Type Inhibition
Cell System LLC-PK1 vesicles-MRP2
Exogenous Factor Genistein Drug in Phase 2 Trial
DT Modulation Genistein induces the transportation of Sorafenib by ABCC2 [18]
Affected Drug/Substrate Sorafenib Modulation Type Inducer
Cell System Human hepatocellular carcinoma cell line (HepG2)-MRP2
DT Modulation Genistein induces the activity of ABCC2 [18]
Cell System Human hepatocellular carcinoma cell line (HepG2)-MRP2
Exogenous Factor Bosentan Approved Drug
DT Modulation Bosentan inhibits the transportation of Estradiol 17b-D-glucuronide by ABCC2 [19]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Exogenous Factor Probenecid Approved Drug
DT Modulation Probenecid inhibits the transportation of SN-38 by ABCC2 [20]
Affected Drug/Substrate SN-38 Modulation Type Inhibition
DT Modulation Probenecid inhibits the activity of ABCC2 [23], [24]
Exogenous Factor Cisplatin Approved Drug
DT Modulation Cisplatin induces the activity of ABCC2 [21]
Cell System Human hepatocellular carcinoma cell line (HepG2)-MRP2
Exogenous Factor Dexamethasone Approved Drug
DT Modulation Dexamethasone induces the activity of ABCC2 [22]
Exogenous Factor Ritonavir Approved Drug
DT Modulation Ritonavir inhibits the activity of ABCC2 [25], [26]
Exogenous Factor Simvastatin Approved Drug
DT Modulation Simvastatin inhibits the transportation of Calcein AM by ABCC2 (IC50 = 25 +/- 2 microM) [12]
Affected Drug/Substrate Calcein AM Modulation Type Inhibition
Cell System Madin-Darby Canine Kidney (MDCK) cells-MRP2
Exogenous Factor Gemifloxacin Approved Drug
DT Modulation Gemifloxacin inhibits the transportation of Erythromycin by ABCC2 (IC50 = 16 microM) [27]
Affected Drug/Substrate Erythromycin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
Exogenous Factor Ketoprofen Approved Drug
DT Modulation Ketoprofen inhibits the transportation of Methotrexate by ABCC2 (IC50 = 1.4 microM) [13]
Affected Drug/Substrate Methotrexate Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MRP2
Exogenous Factor Pyrethroids Natural Product
DT Modulation Pyrethroids inhibits the transportation of Probenecid by ABCC2 (IC50 = 48.2 microM) [28]
Affected Drug/Substrate Probenecid Modulation Type Inhibition
Cell System Human hepatoma HuH-7 cells-MRP2
Exogenous Factor Tetramethrin Natural Product
DT Modulation Tetramethrin inhibits the transportation of Probenecid by ABCC2 (IC50 = 65.5 microM) [28]
Affected Drug/Substrate Probenecid Modulation Type Inhibition
Cell System Human hepatoma HuH-7 cells-MRP2
Exogenous Factor Cigarette smoke condensate Natural Product
DT Modulation Cigarette smoke condensate inhibits the transportation of Rhodamine 123 by ABCC2 (IC50 = 197.4 microM) [29]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human hepatoma HepaRG cells-MRP2
Exogenous Factor Daunorubicin Approved Drug
DT Modulation Daunorubicin inhibits the transportation of Vinblastine by ABCC2 (Ki = 49.4 microM) [4]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
Exogenous Factor Reserpine Approved Drug
DT Modulation Reserpine inhibits the transportation of Vinblastine by ABCC2 (Ki = 295 microM) [4]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
Exogenous Factor Etoposide Approved Drug
DT Modulation Etoposide inhibits the transportation of Vinblastine by ABCC2 (Ki = 756 microM) [4]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
Exogenous Factor Vincristine Approved Drug
DT Modulation Vincristine inhibits the transportation of Vinblastine by ABCC2 (Ki = 802 microM) [4]
Affected Drug/Substrate Vinblastine Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
Exogenous Factor Canagliflozin Approved Drug
DT Modulation Canagliflozin inhibits the activity of ABCC2 (IC50 = 19.3 microM) [30]
Exogenous Factor Delavirdine Approved Drug
DT Modulation Delavirdine inhibits the transportation of 5-Chloromethylfluorescein diacetate by ABCC2 [31]
Affected Drug/Substrate 5-Chloromethylfluorescein diacetate Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
Exogenous Factor Efavirenz Approved Drug
DT Modulation Efavirenz inhibits the transportation of 5-Chloromethylfluorescein diacetate by ABCC2 [31]
Affected Drug/Substrate 5-Chloromethylfluorescein diacetate Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
Exogenous Factor Emtricitabine Approved Drug
DT Modulation Emtricitabine inhibits the transportation of 5-Chloromethylfluorescein diacetate by ABCC2 [31]
Affected Drug/Substrate 5-Chloromethylfluorescein diacetate Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-MRP2
Exogenous Factor Glutathione Approved Drug
DT Modulation Glutathione inhibits the transportation of Dinitrophenyl-glutathione by ABCC2 [32]
Affected Drug/Substrate Dinitrophenyl-glutathione Modulation Type Inhibition
Cell System Madin-Darby Canine Kidney (MDCK) cells-MRP2
Exogenous Factor Cefaclor Approved Drug
DT Modulation Cefaclor inhibits the transportation of Estradiol-17beta-glucuronide by ABCC2 [33]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Spodoptera frugiperda 21-MRP2
Exogenous Factor Cefadroxil Approved Drug
DT Modulation Cefadroxil inhibits the transportation of Estradiol-17beta-glucuronide by ABCC2 [33]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Spodoptera frugiperda 21-MRP2
Exogenous Factor Cefamandole Approved Drug
DT Modulation Cefamandole inhibits the transportation of Estradiol-17beta-glucuronide by ABCC2 [33]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Spodoptera frugiperda 21-MRP2
Exogenous Factor Cefmetazole Approved Drug
DT Modulation Cefmetazole inhibits the transportation of Estradiol-17beta-glucuronide by ABCC2 [33]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Spodoptera frugiperda 21-MRP2
Exogenous Factor Cefoperazone Approved Drug
DT Modulation Cefoperazone inhibits the transportation of Estradiol-17beta-glucuronide by ABCC2 [33]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Spodoptera frugiperda 21-MRP2
Exogenous Factor Cefoxitin Approved Drug
DT Modulation Cefoxitin inhibits the transportation of Estradiol-17beta-glucuronide by ABCC2 [33]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Spodoptera frugiperda 21-MRP2
Exogenous Factor Ceftriaxone Approved Drug
DT Modulation Ceftriaxone inhibits the transportation of Estradiol-17beta-glucuronide by ABCC2 [33]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Spodoptera frugiperda 21-MRP2
Exogenous Factor Cefuroxime Approved Drug
DT Modulation Cefuroxime inhibits the transportation of Estradiol-17beta-glucuronide by ABCC2 [33]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Spodoptera frugiperda 21-MRP2
Exogenous Factor Cephalexin Approved Drug
DT Modulation Cephalexin inhibits the transportation of Estradiol-17beta-glucuronide by ABCC2 [33]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Spodoptera frugiperda 21-MRP2
Exogenous Factor Cephradine Approved Drug
DT Modulation Cephradine inhibits the transportation of Estradiol-17beta-glucuronide by ABCC2 [33]
Affected Drug/Substrate Estradiol-17beta-glucuronide Modulation Type Inhibition
Cell System Spodoptera frugiperda 21-MRP2
Exogenous Factor Aged garlic extract Natural Product
DT Modulation Aged garlic extract induces the transportation of 2,4-Dinitrophenyl-S-glutathione by ABCC2 [34]
Affected Drug/Substrate 2,4-Dinitrophenyl-S-glutathione Modulation Type Inducer
Cell System Human enterocyte-like 2 cell (Caco-2)-MRP2
Exogenous Factor Acitretin Approved Drug
DT Modulation Acitretin inhibits the transportation of Estradiol 17b-D-glucuronide by ABCC2 [19]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Exogenous Factor Drospirenone Approved Drug
DT Modulation Drospirenone inhibits the transportation of Estradiol 17b-D-glucuronide by ABCC2 [19]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Exogenous Factor Losartan Approved Drug
DT Modulation Losartan inhibits the transportation of Estradiol 17b-D-glucuronide by ABCC2 [19]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Exogenous Factor Sulfasalazine Approved Drug
DT Modulation Sulfasalazine inhibits the transportation of Estradiol 17b-D-glucuronide by ABCC2 [19]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Exogenous Factor Troglitazone Approved Drug
DT Modulation Troglitazone inhibits the transportation of Estradiol 17b-D-glucuronide by ABCC2 [19]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Exogenous Factor Sitaxsentan Drug Withdrawn
DT Modulation Sitaxsentan inhibits the transportation of Estradiol 17b-D-glucuronide by ABCC2 [19]
Affected Drug/Substrate Estradiol 17b-D-glucuronide Modulation Type Inhibition
Exogenous Factor Belinostat Approved Drug
DT Modulation Belinostat inhibits the activity of ABCC2 [35]
Cell System Non-small cell lung cancer (NSCLC) cell lines
Exogenous Factor Chenodiol Approved Drug
DT Modulation Chenodiol induces the activity of ABCC2 [36]
Cell System Human hepatocellular carcinoma cell line (HepG2)-MRP2
Exogenous Factor Clotrimazole Approved Drug
DT Modulation Clotrimazole induces the activity of ABCC2 [37]
Cell System Human hepatocellular carcinoma cell line (HepG2)-MRP2
Exogenous Factor Rifampicin Approved Drug
DT Modulation Rifampicin induces the activity of ABCC2 [37], [38], [39], [40]
Cell System Human hepatocellular carcinoma cell line (HepG2)-MRP2
Exogenous Factor Quercetin Approved Drug
DT Modulation Quercetin induces the activity of ABCC2 [41]
Cell System Human enterocyte-like 2 cell (Caco-2)-MRP2
Exogenous Factor Phenobarbital Approved Drug
DT Modulation Phenobarbital induces the activity of ABCC2 [42]
Cell System Hepatocyte-MRP2
Exogenous Factor Mix silybin A silybin B Natural Product
DT Modulation Mix silybin A silybin B inhibits the activity of ABCC2 [43]
Cell System Spodoptera frugiperda 21-MRP2
Exogenous Factor Chinese herb Jianpijiedu Natural Product
DT Modulation Chinese herb Jianpijiedu induces the activity of ABCC2 [44]
Cell System Rat breast carcinoma cell (Walker-256)-MRP2
Exogenous Factor Boldine Natural Product
DT Modulation Boldine induces the activity of ABCC2 [45]
Cell System Model organism in vivo (rat)
Exogenous Factor St Johns wort extract Natural Product
DT Modulation St Johns wort extract induces the activity of ABCC2 [46]
Cell System Model organism in vivo (rat)
Exogenous Factor Green tea extract (1mg/ml) Natural Product
DT Modulation Green tea extract (1mg/ml) inhibits the activity of ABCC2 [47]
Cell System Human gastrointestinal epithelial cell line (LS-180)-MRP2
Exogenous Factor Hyperforin Investigative Drug
DT Modulation Hyperforin induces the activity of ABCC2 [36]
Cell System Hepatocyte-MRP2
Exogenous Factor Arsenic trioxide Approved Drug
DT Modulation Arsenic trioxide induces the activity of ABCC2 [48], [49]
Exogenous Factor Atazanavir Approved Drug
DT Modulation Atazanavir inhibits the activity of ABCC2 [50]
Exogenous Factor Benzbromarone Approved Drug
DT Modulation Benzbromarone induces the activity of ABCC2 [51]
Exogenous Factor Chenodeoxycholic acid Approved Drug
DT Modulation Chenodeoxycholic acid induces the activity of ABCC2 [36], [52], [53]
Exogenous Factor Cimetidine Approved Drug
DT Modulation Cimetidine inhibits the activity of ABCC2 [8]
Exogenous Factor Darunavir Approved Drug
DT Modulation Darunavir inhibits the activity of ABCC2 [50]
Exogenous Factor Eprosartan Approved Drug
DT Modulation Eprosartan induces the activity of ABCC2 [54]
Exogenous Factor Estradiol Approved Drug
DT Modulation Estradiol induces the activity of ABCC2 [55], [56]
Exogenous Factor Estrone Approved Drug
DT Modulation Estrone inhibits the activity of ABCC2 [57]
Exogenous Factor Etodolac Approved Drug
DT Modulation Etodolac inhibits the activity of ABCC2 [13]
Exogenous Factor Gentamicin Approved Drug
DT Modulation Gentamicin induces the activity of ABCC2 [58], [59]
Exogenous Factor Glibenclamide Approved Drug
DT Modulation Glibenclamide inhibits the activity of ABCC2 [60]
Exogenous Factor Hydrocortisone Approved Drug
DT Modulation Hydrocortisone induces the activity of ABCC2 [22]
Exogenous Factor Indinavir Approved Drug
DT Modulation Indinavir inhibits the activity of ABCC2 [25]
Exogenous Factor Itraconazole Approved Drug
DT Modulation Itraconazole inhibits the activity of ABCC2 [61]
Exogenous Factor Ketoconazole Approved Drug
DT Modulation Ketoconazole inhibits the activity of ABCC2 [62]
Exogenous Factor Lansoprazole Approved Drug
DT Modulation Lansoprazole inhibits the activity of ABCC2 [63]
Exogenous Factor Levonorgestrel Approved Drug
DT Modulation Levonorgestrel inhibits the activity of ABCC2 [64]
Exogenous Factor Lopinavir Approved Drug
DT Modulation Lopinavir inhibits the activity of ABCC2 [65]
Exogenous Factor Micafungin Approved Drug
DT Modulation Micafungin inhibits the activity of ABCC2 [66]
Exogenous Factor Midecamycin Approved Drug
DT Modulation Midecamycin inhibits the activity of ABCC2 [67]
Exogenous Factor Mitoxantrone Approved Drug
DT Modulation Mitoxantrone inhibits the activity of ABCC2 [68]
Exogenous Factor Montelukast Approved Drug
DT Modulation Montelukast inhibits the activity of ABCC2 [69]
Exogenous Factor Mycophenolic acid Approved Drug
DT Modulation Mycophenolic acid inhibits the activity of ABCC2 [70]
Exogenous Factor Pravastatin Approved Drug
DT Modulation Pravastatin inhibits the activity of ABCC2 [71]
Exogenous Factor Saquinavir Approved Drug
DT Modulation Saquinavir inhibits the activity of ABCC2 [72], [73]
Exogenous Factor Sulfinpyrazone Approved Drug
DT Modulation Sulfinpyrazone inhibits the activity of ABCC2 [74]
Exogenous Factor Tipranavir Approved Drug
DT Modulation Tipranavir inhibits the activity of ABCC2 [50]
Exogenous Factor Triamcinolone Approved Drug
DT Modulation Triamcinolone induces the activity of ABCC2 [22]
Exogenous Factor Troleandomycin Approved Drug
DT Modulation Troleandomycin induces the activity of ABCC2 [75]
Exogenous Factor Vancomycin Approved Drug
DT Modulation Vancomycin inhibits the activity of ABCC2 [76]
Exogenous Factor Verapamil Approved Drug
DT Modulation Verapamil inhibits the activity of ABCC2 [77]
Exogenous Factor Benzylpenicillin Drug in Phase 3 Trial
DT Modulation Benzylpenicillin induces the activity of ABCC2 [78]
Exogenous Factor Enoxolone Investigative Drug
DT Modulation Enoxolone inhibits the activity of ABCC2 [79]
References
1 Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem Res Toxicol. 2003 Dec;16(12):1642-51.
2 Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999 Dec;56(6):1219-28.
3 Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 1999 Aug;30(2):485-90.
4 Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9.
5 2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2. Eur J Med Chem. 2016 Oct 21;122:408-418.
6 Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation. Pediatr Transplant. 2006 Sep;10(6):707-11.
7 Absence of drug interaction between Hwang-Ryun-Hae-Dok-Tang and phenolsulfonphthalein. Arch Pharm Res. 2010 Dec;33(12):2025-31.
8 Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica. 2005 Jul;35(7):737-53.
9 Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
10 Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. Drug Metab Dispos. 2013 Jan;41(1):149-58.
11 Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP. Pharm Res. 2016 Mar;33(3):590-602.
12 Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
13 Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
14 Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos. 2009 Oct;37(10):2028-36.
15 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
16 Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46.
17 Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer. 2000 Aug;83(3):366-74.
18 Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity. PLoS One. 2015 Mar 17;10(3):e0119502.
19 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
20 The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet. 2002;17(1):23-33.
21 Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7.
22 Rapid, nongenomic stimulation of multidrug resistance protein 2 (Mrp2) activity by glucocorticoids in renal proximal tubule. J Pharmacol Exp Ther. 2011 Jul;338(1):362-71.
23 Role of the multidrug transporter proteins ABCB1 and ABCC2 in the diaplacental transport of talinolol in the term human placenta. Drug Metab Dispos. 2008 Apr;36(4):740-4.
24 Influence of efflux transporters on liver, bile and brain disposition of amitriptyline in mice. Int J Pharm. 2009 Aug 13;378(1-2):80-5.
25 Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 Mar;31(2-3):178-88.
26 Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol. 1999 Aug;56(2):383-9.
27 Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33.
28 Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin. PLoS One. 2017 Jan 18;12(1):e0169480.
29 Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology. 2016 Jul 1;363-364:58-71.
30 In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096.
31 Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos. 2007 Mar;35(3):340-4.
32 Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem J. 1999 Mar 1;338 ( Pt 2):393-401.
33 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
34 Aged garlic extract stimulates p-glycoprotein and multidrug resistance associated protein 2 mediated effluxes. Biol Pharm Bull. 2009 Apr;32(4):694-9.
35 Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat. Lung Cancer. 2017 Jan;103:58-65.
36 Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002 Jan 25;277(4):2908-15.
37 Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46.
38 The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol. 2000 Nov;157(5):1575-80.
39 Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol Cell Biochem. 2010 Apr;337(1-2):133-43.
40 Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol. 2005 Feb 1;69(3):415-23.
41 Coordinate induction by antioxidants of UDP-glucuronosyltransferase UGT1A6 and the apical conjugate export pump MRP2 (multidrug resistance protein 2) in Caco-2 cells. Biochem Pharmacol. 2000 Mar 1;59(5):467-70.
42 Differential regulation of multidrug resistance-associated protein 2 (MRP2) and cytochromes P450 2B1/2 and 3A1/2 in phenobarbital-treated hepatocytes. Biochem Pharmacol. 2002 Jan 15;63(2):333-41.
43 Hepatocellular organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are inhibited by silibinin. Drug Metab Dispos. 2013 Aug;41(8):1522-8.
44 The Chinese Herb Jianpijiedu Contributes to the Regulation of OATP1B2 and ABCC2 in a Rat Model of Orthotopic Transplantation Liver Cancer Pretreated with Food Restriction and Diarrhea. Biomed Res Int. 2015;2015:752850.
45 Boldine enhances bile production in rats via osmotic and farnesoid X receptor dependent mechanisms. Toxicol Appl Pharmacol. 2015 May 15;285(1):12-22.
46 St. John's Wort (Hypericum perforatum) induces overexpression of multidrug resistance protein 2 (MRP2) in rats: a 30-day ingestion study. Food Chem Toxicol. 2004 Jun;42(6):995-1002.
47 Inhibitory activity of a green tea extract and some of its constituents on multidrug resistance-associated protein 2 functionality. Planta Med. 2005 Feb;71(2):135-41.
48 MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus). Toxicol Sci. 2007 May;97(1):103-10.
49 Effects of MRP2-GSH cotransport system on hepatic arsenic metabolism in rats. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2006 May;24(5):278-80.
50 MRP2 Inhibition by HIV Protease Inhibitors in Rat and Human Hepatocytes: A Quantitative Confocal Microscopy Study. Drug Metab Dispos. 2018 May;46(5):697-703.
51 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
52 Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. Aliment Pharmacol Ther. 2007 Oct 15;26(8):1139-46.
53 Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol. 2003 Oct;39(4):480-8.
54 Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61.
55 Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8.
56 Involvement of Mrp2/MRP2 in the species different excretion route of benzylpenicillin between rat and human. Xenobiotica. 2009 Feb;39(2):171-81.
57 Modulation of human multidrug resistance protein (MRP) 1 (ABCC1) and MRP2 (ABCC2) transport activities by endogenous and exogenous glutathione-conjugated catechol metabolites. Drug Metab Dispos. 2008 Mar;36(3):552-60.
58 Increased apical insertion of the multidrug resistance protein 2 (MRP2/ABCC2) in renal proximal tubules following gentamicin exposure. J Pharmacol Exp Ther. 2006 Sep;318(3):1194-202.
59 Short-term exposure of renal proximal tubules to gentamicin increases long-term multidrug resistance protein 2 (Abcc2) transport function and reduces nephrotoxicant sensitivity. J Pharmacol Exp Ther. 2005 Nov;315(2):912-20.
60 Estimation of transporters involved in the hepatobiliary transport of TA-0201CA using sandwich-cultured rat hepatocytes from normal and multidrug resistance-associated protein 2-deficient rats. Drug Metab Dispos. 2010 Sep;38(9):1505-13.
61 Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. Drug Metab Dispos. 2016 Mar;44(3):453-9.
62 CYP1A1 induction and CYP3A4 inhibition by the fungicide imazalil in the human intestinal Caco-2 cells-comparison with other conazole pesticides. Toxicol Lett. 2009 Feb 10;184(3):159-68.
63 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG02867)
64 Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Drug Metab Dispos. 2005 Nov;33(11):1576-9.
65 Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. Int J Pharm. 2008 Jul 9;359(1-2):7-14.
66 Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP. Antimicrob Agents Chemother. 2016 May 23;60(6):3372-9.
67 Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet. 2003;18(1):16-22.
68 Presence or absence of a gallate moiety on catechins affects their cellular transport. J Pharm Pharmacol. 2008 Sep;60(9):1189-95.
69 Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. Biol Pharm Bull. 2009 Dec;32(12):2002-9.
70 C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007 Sep;8(9):1127-41.
71 Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002 Jan 17;78(1-3):43-54.
72 Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS. 2002 Nov 22;16(17):2295-301.
73 Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44.
74 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
75 Interactions of pharmaceuticals and other xenobiotics on key detoxification mechanisms and cytoskeleton in Poeciliopsis lucida hepatocellular carcinoma, PLHC-1 cell line. Toxicol In Vitro. 2013 Feb;27(1):111-20.
76 JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats. Toxicol Lett. 2018 Oct 1;295:195-204.
77 Molecular mechanisms of biliary excretion of cefditoren and the effects of cefditoren on the expression levels of hepatic transporters. Drug Metab Pharmacokinet. 2010;25(4):320-7.
78 Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8.
79 Inhibitory effects of terpenoids on multidrug resistance-associated protein 2- and breast cancer resistance protein-mediated transport. Drug Metab Dispos. 2008 Jul;36(7):1206-11.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.